CAJ | 학술논문

目的总结氟维司群治疗受体阳性晚期乳腺癌的临床疗效及不良反应.方法选取2011年8月-2012年5月于我科使用氟维司群治疗的27例患者临床资料,观察其疾病进展时间、有效率、临床获益率及不良反应.结果中位疾病进展时间4.8个月,客观有效率(objective response rate,ORR)14.81%(4/27),临床获益率(CR+PR+SD>3个月)48.15%(13/27).主要不良反应为乏力、食欲减退.结论氟维司群是他莫昔芬及芳香化酶抑制剂治疗失败后受体阳性晚期乳腺癌的有效药物,且耐受性好.
목적총결불유사군치료수체양성만기유선암적림상료효급불량반응.방법선취2011년8월-2012년5월우아과사용불유사군치료적27례환자림상자료,관찰기질병진전시간、유효솔、림상획익솔급불량반응.결과중위질병진전시간4.8개월,객관유효솔(objective response rate,ORR)14.81%(4/27),림상획익솔(CR+PR+SD>3개월)48.15%(13/27).주요불량반응위핍력、식욕감퇴.결론불유사군시타막석분급방향화매억제제치료실패후수체양성만기유선암적유효약물,차내수성호.
Objective To observe the therapeutic effect and toxicity of fulvestrant on estrogen receptor (ER)-positive advanced breast cancer. Methods Twenty-seven patients who received fulvestrant treatment in our hospital from August 2011 to May 2012 were enrolled in this study. Their clinical data including the disease progression time, overall response rate, clinical beneficial rate, and side effects were analyzed. Results The median disease progression time, objective response rate, and 3-month clinical beneficial rate were 4.8 months, 14.81%(4/27), and 48.15%(13/27), respectively. The main side effects were fatigue and anorexia. Conclusion Fulvestrant is a well-tolerated and effective drug for ER-positive advanced breast cancer when it fails to respond to tamoxifen and aromatase inhibitors.